Neutralizing monoclonal antibodies against highly pathogenic coronaviruses

IF 5.7 2区 医学 Q1 VIROLOGY
Rong Xiang , Yang Wang , Lili Wang , Xiaoqian Deng , Shanshan Huo , Shibo Jiang , Fei Yu
{"title":"Neutralizing monoclonal antibodies against highly pathogenic coronaviruses","authors":"Rong Xiang ,&nbsp;Yang Wang ,&nbsp;Lili Wang ,&nbsp;Xiaoqian Deng ,&nbsp;Shanshan Huo ,&nbsp;Shibo Jiang ,&nbsp;Fei Yu","doi":"10.1016/j.coviro.2021.12.015","DOIUrl":null,"url":null,"abstract":"<div><p>The pandemic of Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome 2 coronavirus (SARS-CoV-2) is a continuing worldwide threat to human health and social economy. Historically, SARS-CoV-2 follows SARS and MERS as the third coronavirus spreading across borders and continents, but far more dangerous with long-lasting symptomatic consequences. The current situation is strong evidence that coronaviruses will continue to be pathogens of consequence in the future, thus calling for the development of neutralizing antibody-based prophylactics and therapeutics for prevention and treatment of COVID-19 and other human coronavirus diseases. This review summarized the progresses of developing neutralizing monoclonal antibodies against infection of SARS-CoV-2, SARS-CoV, and MERS-CoV, and discussed their potential applications in prevention and treatment of COVID-19 and other human coronavirus diseases.</p></div>","PeriodicalId":11082,"journal":{"name":"Current opinion in virology","volume":"53 ","pages":"Article 101199"},"PeriodicalIF":5.7000,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716168/pdf/","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current opinion in virology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1879625721001723","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"VIROLOGY","Score":null,"Total":0}
引用次数: 3

Abstract

The pandemic of Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome 2 coronavirus (SARS-CoV-2) is a continuing worldwide threat to human health and social economy. Historically, SARS-CoV-2 follows SARS and MERS as the third coronavirus spreading across borders and continents, but far more dangerous with long-lasting symptomatic consequences. The current situation is strong evidence that coronaviruses will continue to be pathogens of consequence in the future, thus calling for the development of neutralizing antibody-based prophylactics and therapeutics for prevention and treatment of COVID-19 and other human coronavirus diseases. This review summarized the progresses of developing neutralizing monoclonal antibodies against infection of SARS-CoV-2, SARS-CoV, and MERS-CoV, and discussed their potential applications in prevention and treatment of COVID-19 and other human coronavirus diseases.

Abstract Image

Abstract Image

抗高致病性冠状病毒的中和单克隆抗体
由严重急性呼吸综合征2型冠状病毒(SARS-CoV-2)引起的2019冠状病毒病(COVID-19)大流行是对人类健康和社会经济的持续全球威胁。从历史上看,SARS- cov -2是继SARS和MERS之后的第三种跨国界和跨大陆传播的冠状病毒,但其危险程度要高得多,会产生长期的症状后果。目前的情况有力地证明,冠状病毒在未来仍将是重要的病原体,因此需要开发基于中和抗体的预防和治疗方法,以预防和治疗COVID-19和其他人类冠状病毒疾病。本文综述了抗SARS-CoV-2、SARS-CoV和MERS-CoV感染的中和性单克隆抗体的研究进展,并讨论了它们在预防和治疗COVID-19和其他人类冠状病毒疾病中的潜在应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
11.80
自引率
5.10%
发文量
76
审稿时长
83 days
期刊介绍: Current Opinion in Virology (COVIRO) is a systematic review journal that aims to provide specialists with a unique and educational platform to keep up to date with the expanding volume of information published in the field of virology. It publishes 6 issues per year covering the following 11 sections, each of which is reviewed once a year: Emerging viruses: interspecies transmission; Viral immunology; Viral pathogenesis; Preventive and therapeutic vaccines; Antiviral strategies; Virus structure and expression; Animal models for viral diseases; Engineering for viral resistance; Viruses and cancer; Virus vector interactions. There is also a section that changes every year to reflect hot topics in the field.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信